Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed advanced stomach or gastroesophageal junction cancer that failed or became intolerable on first-line treatment
- At least one measurable tumor lesion visible on imaging
- Adequate blood counts, liver, and kidney function; controlled protein in urine
- Good overall health (ECOG performance status 0–1) with at least 12 weeks life expectancy
- No active heart disease, uncontrolled high blood pressure, or active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of paclitaxel polymeric micelles and fruquintinib capsules as a second-line treatment for patients with advanced gastric cancer whose first-line therapy with oxaliplatin and fluorouracil has stopped working. The goal is to see if this new drug combination can shrink tumors and how safe it is.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.